Does early dual therapy improve outcomes for staph bloodstream infections?
Part of Infections clinical trials.
This study looks at whether giving two antibiotics early for a serious staph infection in the blood leads to better results than the standard one antibiotic. It uses existing hospital monitoring and follow-up visits to track progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently in one of the listed hospitals in West Virginia.
- You tested positive for staph in your bloodstream (Staphylococcus aureus bacteremia).
- You can attend lab check-ups and follow-up visits in person or by video.
- You or your family decision-maker must agree to join the study.
- You are not pregnant, a prisoner, or mentally disabled.
- The hospital team decides it is safe for you to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different combinations of antibiotics to treat a staph infection in the blood. If you're in an Intermountain hospital with this infection, the trial may help doctors find the most effective treatment for you.
This trial tests whether switching from IV antibiotics to oral antibiotics after 3–7 days is safe and effective for people with uncomplicated Staphylococcus aureus bloodstream infections. It may help you avoid a longer hospital stay and reduce IV-related complications.
This trial tests the best treatment approach for bloodstream infections caused by Staphylococcus aureus (“S. aureus”). It uses a flexible design to decide which treatment track you fit into, and may help improve recovery while avoiding unnecessary medications.
This trial compares two antibiotics, vancomycin and daptomycin, to see which works better for treating MRSA bacteria in the blood. Patients are randomly assigned to one of the drugs and will be monitored closely for results and side effects.
This study looks at different types of Staph aureus blood infections to understand which ones are more likely to cause severe illness or death. It may help doctors predict who needs more aggressive treatment.
This Phase 2 study tests whether adding ertapenem to cefazolin can improve treatment of staphylococcus (“S. aureus”) bloodstream infection that is likely methicillin-susceptible (MSSA). It aims to start the right antibiotics quickly, before MRSA status is fully confirmed, using early testing and a treatment plan guided by infectious-disease specialists.
Hear when a new Staphylococcus Aureus Bacteremia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.